Meitav Investment House Ltd. Sells 13,294 Shares of Urogen Pharma $URGN

Meitav Investment House Ltd. lowered its holdings in Urogen Pharma (NASDAQ:URGN) by 37.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,223 shares of the company’s stock after selling 13,294 shares during the period. Meitav Investment House Ltd.’s holdings in Urogen Pharma were worth $400,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Urogen Pharma by 7.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after buying an additional 1,653 shares during the last quarter. Main Street Financial Solutions LLC raised its position in Urogen Pharma by 8.2% in the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after acquiring an additional 1,968 shares during the period. Barclays PLC raised its position in Urogen Pharma by 3.8% in the fourth quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after acquiring an additional 2,125 shares during the period. Finally, Osaic Holdings Inc. boosted its stake in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares during the last quarter. Institutional investors own 91.29% of the company’s stock.

Insider Transactions at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $35.01, for a total transaction of $350,100.00. Following the sale, the insider owned 129,763 shares of the company’s stock, valued at approximately $4,543,002.63. This represents a 7.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.80% of the company’s stock.

Wall Street Analyst Weigh In

URGN has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of Urogen Pharma in a research note on Wednesday, June 3rd. LADENBURG THALM/SH SH began coverage on Urogen Pharma in a research note on Monday, May 11th. They issued a “buy” rating and a $43.00 price objective on the stock. Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $33.00 price target on shares of Urogen Pharma in a research report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.50.

Urogen Pharma Trading Up 0.9%

Shares of URGN stock opened at $37.75 on Wednesday. The firm’s 50 day moving average is $30.37 and its 200 day moving average is $24.10. The stock has a market capitalization of $1.84 billion, a P/E ratio of -13.73 and a beta of 1.56. Urogen Pharma has a 12 month low of $13.26 and a 12 month high of $39.58.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million for the quarter, compared to analysts’ expectations of $44.83 million. On average, equities analysts predict that Urogen Pharma will post -0.88 EPS for the current year.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.